TAURIGA SCIENCES INC - TAUG STOCK NEWS

Tauriga Sciences, Inc. (OTCQB: TAUG) announced on September 10, 2021, the renewal of its U.S. Federal Government Vendor status, enhancing its potential for government contracts. The Company, which has significantly diversified its product lines, collaborates with Federal Award Management Registration to identify contract opportunities, particularly with the Department of Defense. Additionally, Tauriga will exhibit at the USA CBD EXPO CHICAGO from October 28-30, 2021. The company focuses on CBD and CBG edible products, including its flagship Tauri-Gum™ brand.

Tauriga Sciences, Inc. (OTCQB: TAUG) has fully repaid its $135,000 Non-Convertible inventory factoring credit facility a month early, demonstrating improved financial health. The repayment included five installments of $21,214.29 and a final installment of $42,428.58. Initially structured with a 10% annual interest rate and a grace period, the repayment signifies the company's growing retail business and fiscal responsibility.

Tauriga Sciences, Inc. (TAUG) has initiated a clinical trial to assess the effects of Cannabidiol (CBD) on pregnant women suffering from Hyperemesis Gravidarum, a severe form of morning sickness. The trial will be a double-blind, placebo-controlled study, focusing on varying CBD doses to alleviate nausea. This marks a significant step in the company's pharmaceutical development strategy, utilizing its proprietary CBD-infused chewing gum for sublingual delivery. The Chief Medical Officer, Dr. Keith Aqua, emphasizes the need for rigorous scientific data on cannabinoid effects in pregnant populations.

Tauriga Sciences (OTCQB: TAUG) announces participation at the Hampton Cannabis Expo on August 22, 2021, in East Hampton, NY, showcasing its Tauri-Gum products. The expo aims to connect investors and industry leaders amid expanding business opportunities in New York. Additionally, Tauriga will be present at the AATAC Convenience Store Tradeshow on September 22-23, 2021, in Richmond, VA, which includes over 50,000 retail operators. The company focuses on expanding its Tauri-Gum product line and is set to participate in five major trade shows by year-end.

Tauriga Sciences, Inc. (TAUG) has released a positive update for its 2nd Fiscal Quarter 2022, highlighting recovery from COVID-19 production delays and strong growth in its E-Commerce and Retail segments. The company has generated record quarterly revenue in just six weeks and successfully launched its enhanced Tauri-Gum™ product line, which drives revenue growth. Moreover, discussions are ongoing with potential distributors and retail partners to enhance shareholder value. The company is also advancing its pharmaceutical development of a cannabinoid-based Tauri-Gum™ for chemotherapy-related nausea.

Tauriga Sciences (TAUG) has unveiled its schedule for upcoming in-person tradeshows after being limited to virtual events since March 2020 due to the pandemic. The company will showcase its innovative products at three major events: White Label World Expo in New York (Sept 30 - Oct 1), MJBizCon in Las Vegas (Oct 19 - 22), and Kosherfest 2021 in Secaucus (Nov 9 - 10). This initiative aims to connect with buyers, distributors, and interested parties, enhancing visibility in the CBD and CBG markets.

Tauriga Sciences, Inc. (TAUG) has announced the arrival of product inventory for its enhanced Tauri-Gum™ line, featuring 11 SKUs available immediately on its e-commerce site. The enhanced product line includes various CBD and CBG flavored gum options, vital nutrient-infused variants, and collaborative products with Think Big, LLC. The company is preparing for a commercial launch to retail customers while continuing to develop a pharmaceutical-grade version aimed at nausea regulation for chemotherapy patients, following a patent application conversion.

Tauriga Sciences, Inc. (TAUG) confirmed strong momentum in its 2nd Fiscal Quarter 2022, reporting July 2021 net revenues exceeding $60,000. The company is seeing increased demand for its Tauri-Gum™ product line, including the newly launched Delta 8 THC chewing gum. Enhanced manufacturing processes have resulted in cost savings without compromising quality. Tauriga is focused on expanding its customer base and revenue growth, with ongoing initiatives in the CBD and CBG edibles market, alongside its pharmaceutical development efforts targeting nausea regulation for chemotherapy patients.

Tauriga Sciences, Inc. (OTCQB: TAUG) reported a record E-Commerce revenue of over $13,000 from nearly 200 transactions on July 25, 2021. This surge in sales was fueled by the arrival of new product inventory, including various TAURI and CBD-infused products. The company anticipates further growth with the upcoming inventory of its Tauri-Gum™ products, set to fulfill pre-orders and engage prospective retail customers. Tauriga focuses on the Cannabidiol and Cannabigerol Edibles market and operates two fulfillment centers in Texas and New York.